Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Bimatoprost Topical Solution in the Treatment of Androgenetic Alopecia in Men
Phase of Trial: Phase I
Latest Information Update: 20 Mar 2017
At a glance
- Drugs Bimatoprost (Primary)
- Indications Alopecia
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Allergan
- 15 Mar 2017 Status changed from recruiting to discontinued.
- 22 Sep 2016 Planned End Date changed from 1 Apr 2017 to 1 Oct 2017.
- 22 Sep 2016 Planned primary completion date changed from 1 Apr 2017 to 1 Oct 2017.